PUBLIC COMPANY
save$QTTBQ32 Bio Inc.
$QTTB15.39+2.06%Waltham, MA, USupdated 2mo ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
🐶 Hiring Signal
News
- Chutes & Ladders—Legend poaches Novartis vet to boost commercial potentialAfter former Legend Biotech CEO Ying Huang, Ph.D., left the company suddenly in July, Legend has found its permanent CEO, poaching Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its nex…fiercebiotech · 16d ago
- Erasca's $550M offering; Summit sells an antibioticPlus, news about subcutaneous Leqembi, WuXi AppTec and Q32 Bio. 📊 Erasca targets $550M for KRAS drugs: The biotech's public offering came after it shared a small ...endpoints · 2mo ago
- Q32 bounces back to claim study success for alopecia drugNearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed investors’ expectations.biopharma_dive · 2mo ago
- Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trialPlus, news about Insilico, Ipsen, Q32 Bio, GSK’s Jemperli, Drug Farm and Padcev. ❌ FDA rejects Tris Pharma’s narcolepsy drug: Its rejection letter said that “additional information will be necessar…endpoints · 2mo ago
Data sources
last refreshed 20m ago
Found something off?
comments(0)
5-min edit window · permanent after that